EGFR and adenocarcinoma: A systematic review of 27 studies [32] reported that the EGFR mutation rate was the highest in lepidic predominant adenocarcinoma (LPA) (50.7%), while SPA (p < 0.01) and invasive mucinous adenocarcinoma (IMA) (p < 0.01) were associated with the EGFR-wild status.